Tags

Type your tag names separated by a space and hit enter

Comparison of 24-hour insulin requirements in IDDM patients during control by an artificial betacell and during conventional therapy.
Horm Metab Res. 1981 Oct; 13(10):537-41.HM

Abstract

Insulin requirements were measured over 24 hours during feed-back control by an artificial betacell (Biostator) in 25 lean insulin-dependent diabetics with no endogenous insulin secretion. The set of constants selected for the algorithms was that which resulted in the minimum insulin infusion consistent with normal glucose tolerance during an OGTT. The results were compared with the daily dose of insulin chosen, using standard clinical criteria, by physicians with no knowledge of the experimental results. Plasma IRI remained within the normal range during Biostator control, and the insulin dose given over 24 hours was almost identical - 101 +/- 9% with that selected on clinical grounds. The reproducibility of insulin requirements established with the Biostator was tested over two consecutive days in nine patients; all required an increased amount of insulin (mean + 6.9%, range + 0.5 to + 12.2%) on the second day.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

7028586

Citation

Christiansen, J S., et al. "Comparison of 24-hour Insulin Requirements in IDDM Patients During Control By an Artificial Betacell and During Conventional Therapy." Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 13, no. 10, 1981, pp. 537-41.
Christiansen JS, Svendsen PA, Mathiesen E, et al. Comparison of 24-hour insulin requirements in IDDM patients during control by an artificial betacell and during conventional therapy. Horm Metab Res. 1981;13(10):537-41.
Christiansen, J. S., Svendsen, P. A., Mathiesen, E., Rubin, P., & Deckert, T. (1981). Comparison of 24-hour insulin requirements in IDDM patients during control by an artificial betacell and during conventional therapy. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 13(10), 537-41.
Christiansen JS, et al. Comparison of 24-hour Insulin Requirements in IDDM Patients During Control By an Artificial Betacell and During Conventional Therapy. Horm Metab Res. 1981;13(10):537-41. PubMed PMID: 7028586.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of 24-hour insulin requirements in IDDM patients during control by an artificial betacell and during conventional therapy. AU - Christiansen,J S, AU - Svendsen,P A, AU - Mathiesen,E, AU - Rubin,P, AU - Deckert,T, PY - 1981/10/1/pubmed PY - 1981/10/1/medline PY - 1981/10/1/entrez SP - 537 EP - 41 JF - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme JO - Horm Metab Res VL - 13 IS - 10 N2 - Insulin requirements were measured over 24 hours during feed-back control by an artificial betacell (Biostator) in 25 lean insulin-dependent diabetics with no endogenous insulin secretion. The set of constants selected for the algorithms was that which resulted in the minimum insulin infusion consistent with normal glucose tolerance during an OGTT. The results were compared with the daily dose of insulin chosen, using standard clinical criteria, by physicians with no knowledge of the experimental results. Plasma IRI remained within the normal range during Biostator control, and the insulin dose given over 24 hours was almost identical - 101 +/- 9% with that selected on clinical grounds. The reproducibility of insulin requirements established with the Biostator was tested over two consecutive days in nine patients; all required an increased amount of insulin (mean + 6.9%, range + 0.5 to + 12.2%) on the second day. SN - 0018-5043 UR - https://www.unboundmedicine.com/medline/citation/7028586/Comparison_of_24_hour_insulin_requirements_in_IDDM_patients_during_control_by_an_artificial_betacell_and_during_conventional_therapy_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-1019328 DB - PRIME DP - Unbound Medicine ER -